PMID- 36356335
OWN - NLM
STAT- MEDLINE
DCOM- 20221213
LR  - 20231213
IS  - 1618-0631 (Electronic)
IS  - 0344-0338 (Linking)
VI  - 240
DP  - 2022 Dec
TI  - Circular RNA ciRS-7 promotes laryngeal squamous cell carcinoma development by 
      inducing TGM3 hypermethylation via miR-432-5p/DNMT3B axis.
PG  - 154193
LID - S0344-0338(22)00437-X [pii]
LID - 10.1016/j.prp.2022.154193 [doi]
AB  - OBJECTIVE: This work is to explore the mechanism by which circular RNA ciRS-7 
      affects laryngeal squamous cell carcinoma (LSCC). METHODS: ciRS-7 expression in 
      LSCC tissues was detected by qRT-PCR, and the association between ciRS-7 with 
      clinicopathological features of LSCC patients was evaluated. HN-4 and UM-SCC-10A 
      cells were transfected or cotransfected with si-ciRS-7, miR-432-5p inhibitor, 
      LV-DNMT3B or si-TGM3. Then, the viability and aggressive nature of the cells were 
      tested. The binding site between ciRS-7 and miR-432-5p or between miR-432-5p and 
      DNMT3B was predicted and the targeting relationship was identified. The specific 
      binding between ciRS-7 and miR-432-5p was further verified by AGO2 RIP assay. 
      HN-4 cells transfected with si-ciRS-7 was injected into nude mice to induce 
      xenograft tumors. RESULTS: Higher ciRS-7 expression in LSCC tissues was closely 
      associated with higher clinical stage, and exacerbated infiltration and lymph 
      node metastasis in LSCC patients. Silencing ciRS-7 inhibited LSCC cell viability, 
      epithelial-mesenchymal transition (EMT), and promoted the apoptosis. When 
      miR-432-5p was inhibited or DNMT3B was overexpressed, the growth and EMT of LSCC 
      cells were stimulated despite ciRS-7 silencing. Downregulation of ciRS-7 
      restrained the growth of xenograft tumors in vivo. CONCLUSION: ciRS-7 promotes 
      the progression of LSCC through increasing TGM3 methylation via miR-432-5p/DNMT3B 
      axis.
CI  - Copyright (c) 2022 Elsevier GmbH. All rights reserved.
FAU - Zhao, Kun
AU  - Zhao K
AD  - Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, Henan 450052, PR China.
FAU - Ye, Fanglei
AU  - Ye F
AD  - Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, Henan 450052, PR China.
FAU - Gao, Pei
AU  - Gao P
AD  - Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, Henan 450052, PR China.
FAU - Zhu, Xiaodan
AU  - Zhu X
AD  - Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, Henan 450052, PR China.
FAU - Hao, Shaojuan
AU  - Hao S
AD  - Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, Henan 450052, PR China.
FAU - Lou, Weihua
AU  - Lou W
AD  - Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, Henan 450052, PR China. Electronic address: 
      louweihua1618@163.com.
LA  - eng
PT  - Journal Article
DEP - 20221030
PL  - Germany
TA  - Pathol Res Pract
JT  - Pathology, research and practice
JID - 7806109
RN  - 0 (MicroRNAs)
RN  - 0 (MIRN432 microRNA, human)
RN  - 0 (RNA, Circular)
RN  - EC 2.3.2.13 (TGM3 protein, human)
RN  - EC 2.3.2.13 (Transglutaminases)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Mice
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Gene Expression Regulation, Neoplastic/genetics
MH  - *Head and Neck Neoplasms/genetics
MH  - *Laryngeal Neoplasms/pathology
MH  - Mice, Nude
MH  - *MicroRNAs/genetics/metabolism
MH  - RNA, Circular/genetics
MH  - Squamous Cell Carcinoma of Head and Neck/genetics
MH  - Transglutaminases/genetics/metabolism
MH  - DNA Methyltransferase 3B
OTO - NOTNLM
OT  - Circular RNA ciRS-7
OT  - DNMT3B
OT  - Epithelial-mesenchymal transition
OT  - Invasion
OT  - Laryngeal squamous cell carcinoma
OT  - MiR-432-5p
OT  - Proliferation
OT  - TGM3
COIS- Declaration of Competing Interest No conflicts of interest, financial or 
      otherwise, are declared by the authors.
EDAT- 2022/11/11 06:00
MHDA- 2022/12/07 06:00
CRDT- 2022/11/10 18:14
PHST- 2022/04/26 00:00 [received]
PHST- 2022/09/08 00:00 [revised]
PHST- 2022/10/27 00:00 [accepted]
PHST- 2022/11/11 06:00 [pubmed]
PHST- 2022/12/07 06:00 [medline]
PHST- 2022/11/10 18:14 [entrez]
AID - S0344-0338(22)00437-X [pii]
AID - 10.1016/j.prp.2022.154193 [doi]
PST - ppublish
SO  - Pathol Res Pract. 2022 Dec;240:154193. doi: 10.1016/j.prp.2022.154193. Epub 2022 
      Oct 30.